高级别脑胶质瘤术后同步加量调强放疗和术后序贯加量调强放疗的效果比较  

Comparison Effect of Postoperative Simultaneous Integrated Boost Intensity-modulated Radiotherapy and Postoperative Sequential Boost Intensity-modulated Radiotherapy for High-grade Glioma

作　　者：包德强[1] 吴畅 杨东晓 李泳慧[1] BAO Deqiang;WU Chang;YANG Dongxiao;LI Yonghui(The First Naval Hospital of Southern Theater Command of the Southern Theater Command of the People's Liberation Army of China,Zhanjiang 524009,China;不详)

机构地区：[1]中国人民解放军南部战区海军第一医院,广东湛江524009

出　　处：《中外医学研究》2023年第27期14-18,共5页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:比较高级别脑胶质瘤术后同步加量调强放疗与术后序贯加量调强放疗的效果。方法:选择2018年4月—2020年6月中国人民解放军南部战区海军第一医院收治的80例高级别脑胶质瘤患者作为研究对象,根据随机数表法将患者分为研究组和对照组,各40例。研究组接受术后同步加量调强放疗,对照组接受术后序贯加量调强放疗。比较两组疗效、炎症指标[人多效生长因子(human pleiotrophin,PTN)、白细胞介素-6(interleukin-6,IL-6)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)]、血清标志物[表皮生长因子(epidermal growth factor,EGF)、血管内皮生长因子(vascular endothelial growth factor,VEGF)]、不良反应、复发与生存、生活质量(quality of life,QOL)评分与体力状况评分[采用Karnofsky功能状态(Karnofsky performance status scale,KPS)]。结果:研究组总有效率为85.00%,高于对照组的65.00%,差异有统计学意义(P<0.05)。两组治疗前炎症指标、血清标志物、QOL评分、KPS评分比较,差异无统计学意义(P>0.05);研究组放疗8周后PTN、IL-6、TNF-α、EGF、VEGF均低于对照组,但QOL评分、KPS评分高于对照组,差异有统计学意义(P<0.05)。研究组不良反应发生率为20.00%,低于对照组的42.50%,差异有统计学意义(P<0.05)。研究组1年、2年生存率均高于对照组,但复发率为20.59%(7/34),低于对照组的46.15%(12/26),差异有统计学意义(P<0.05)。结论:高级别脑胶质瘤术后同步加量调强放疗较序贯加量调强放疗的效果更理想,能减轻炎症反应,改善血清标志物水平,同时提升患者生活质量,不良反应及复发少,生存率高。Objective:To compare the effect of postoperative simultaneous integrated boost intensity-modulated radiotherapy and postoperative sequential boost intensity-modulated radiotherapy for high-grade glioma.Method:A total of 80 patients with highgrade glioma who admitted to the First Naval Hospital of Southern Theater Command of the Southern Theater Command of the People's Liberation Army of China from April 2018 to June 2020 were selected as the research objects,the patients were divided into the study group and the control group according to the random number table method,40 cases in each group.The study group was given postoperative simultaneous integrated boost intensity-modulated radiotherapy,and the control group was given postoperative sequential boost intensity-modulated radiotherapy.The efficacy,inflammatory indicators[human pleiotrophin(PTN),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)],serum markers[epidermal growth factor(EGF),vascular endothelial growth factor(VEGF)],adverse reactions,recurrence and survival,quality of life(QOL)score and physical condition score[Karnofsky performance status scale(KPS)]were compared between two groups.Result:The total effective rate of the study group was 85.00%,which was higher than 65.00%of the control group,and the difference was statistically significant(P<0.05).There were no significant differences in inflammatory indexes,serum markers,QOL score and KPS score between two groups before treatment(P>0.05);after 8 weeks of radiotherapy,the PTN,IL-6,TNF-α,EGF and VEGF in the study group were lower than those in the control group,but QOL score and KPS score were higher than those in the control group,and the differences were statistically significant(P<0.05).The adverse reactions of the study group was 20.00%,which was lower than 42.50%of the control group,and the difference was statistically significant(P<0.05).The 1-year and 2-year survival rates of the study group were higher than those of the control group,but the recurrence rate was 20.59%(7/34)lower than 46.1

关 键 词：高级别脑胶质瘤 序贯加量调强放疗 同步加量调强放疗 

分 类 号：R739.4[医药卫生—肿瘤] R730.55[医药卫生—临床医学]